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ABSTRACT 32 
Nanomaterials convey numerous advantages, and the past decade has seen a considerable rise in 33 
their development and production for an expanse of applications. While the potential advantages of 34 
nanomaterials are clear, concerns over the impact of human and environmental exposure exist. 35 
Concerted, science-led efforts are required to understand the effects of nanomaterial exposure and 36 
ensure that protection goals are met. There is much on-going discussion regarding how best to 37 
assess nanomaterial risk, particularly considering the large number of tests that may be required. A 38 
plethora of forms may need to be tested for each nanomaterial, and risk assessed throughout the 39 
life cycle, meaning numerous acute and chronic toxicity studies could be required, which is neither 40 
practical nor utilises the current evidence-base. Hence, there is scientific, business, ethical and 41 
legislative drivers to re-consider the use of animal toxicity tests. An expert Working Group of 42 
regulators, academics and industry scientists were gathered by the UK’s NC3Rs to discuss: i) 43 
opportunities being offered in the short, medium and long-terms to advance nanosafety, ii) how to 44 
align these advances with the application of the 3Rs in nanomaterial safety testing, and iii) shifting 45 
the focus of risk assessment from current hazard-based approaches towards exposure-driven 46 
approaches. 47 
 48 
KEY WORDS (max. 6) 49 
3Rs; alternative approaches; nanotoxicology; nanosafety; regulatory testing; in vitro/in silico 50 
 51 
ABBREVIATIONS 52 
AOP  Adverse outcome pathway 53 
ECETOC  European Centre for Ecotoxicology and Toxicology of Chemicals 54 
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1. Introduction 70 
Due to their unique physicochemical properties, the potential utility of nanomaterials has been 71 
increasingly recognised over recent years. A nanomaterial can be defined as a material which has at 72 
least one dimension between 1 and 100 nm in diameter (ISO, 2008). However, there are currently 73 
multiple working definitions of a nanomaterial, which means that materials not specifically designed 74 
as nanomaterials can in some instances also be classified as “nano”, if for example they contain a 75 
fraction in the nano-sized range of >50% of the particle count, as per the EU Recommendation (EC, 76 
2011). There exists a vast array of different nanomaterials and forms that have been placed on the 77 
market for numerous applications across a wide range of sectors such as cosmetics, medicine, 78 
agriculture, food, textiles, electronics, packaging, and industrial chemicals (e.g. pigments (such as in 79 
paints) and construction chemicals; (Nowack, 2015)). Although the many advantages to their use are 80 
clear, concerns over their safety remain. In particular it will be useful to consider the following when 81 
identifying the potential risks associated with nanomaterials (Stone et al., 2016b): 82 
 What are the potential consequences of nanomaterial exposure for human health and the 83 
environment?  84 
 To what degree are humans actually exposed to nanomaterials (i.e., the likelihood that they 85 
pose a risk where there is a known hazardous potential)?  86 
 What intrinsic and system-dependent physicochemical properties of nanomaterials confer 87 
their toxicity?  88 
 What are the mechanism of actions underlying the toxicity of nanomaterials?  89 
 What are the short and long-term effects of nanomaterial exposure (single, and repeated), 90 
and consequences of the bioaccumulation of insoluble and biopersistent nanomaterials?  91 
Data on the hazard potential of nanomaterials is a necessary component of risk assessments (where 92 
information from both hazard and exposure assessment are combined to establish safe margins of 93 
exposure) and for classification and labelling purposes, to enable registration for marketing and sale. 94 
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There are increasing examples, particularly within Europe, where re-evaluations and/or separate 95 
evaluations of the safety of different nanoforms are required such as the EU Biocides Regulation 96 
(528/2012), the EU Cosmetics Regulation 1223/2009/EC and EU Food Additive Regulation (EC 97 
1333/2008). The European Food Safety Authority (EFSA) has also published Guidance on risk 98 
assessment of nanomaterials in food/feed and the European Commission’s Scientific Committee on 99 
Consumer Safety (SCCS) has released Guidance on risk assessment of nanomaterials in cosmetics. 100 
The US FDA has also recently published Guidance for Industry Use of Nanomaterials in Food for 101 
Animals (FDA, 2015). Authorisations specifically referring to (nano)materials within size boundaries 102 
and/or specific forms may imply that each form of a nanomaterial used in regulated products will 103 
have to be tested for safety in its own right under the appropriate regulatory framework, even 104 
though some of these materials have been in production and use for many years. This approach 105 
could lead to extensive testing of different nanomaterial forms, resulting from for example from 106 
modifications to their size, geometry, and/or surface coatings. A desire to understand the behaviour 107 
of nanomaterials throughout their life cycle/value chain could also potentially contribute towards  108 
an increase in the amount of testing to understand the potential hazards to the consumer and the 109 
environment at different stages of the lifecycle. Generally, the toxicity testing of nanomaterials and 110 
bulk forms for regulatory purposes has been carried out primarily using a prescriptive list of animal 111 
studies which have been traditionally used in the risk assessment of chemicals (e.g. studies 112 
conducted in line with OECD Test Guidelines; 113 
http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm).  114 
There are however increasing pressures to move away from using traditional toxicity testing where 115 
possible (EC, 2014). For example, there are emerging legislative bans on the use of animals in 116 
cosmetics testing, and there has been much debate within the field around whether the traditional 117 
testing strategies for chemical risk assessment are appropriate for nanomaterials (in a broad sense, 118 
and related to the suitability of specific assays)(Nel et al., 2013, Silbergeld et al., 2011, Stone et al., 119 
2016a, Aschberger et al., 2016). For the sustainable development and use of nanomaterials, it is 120 
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crucial that the genuine health implications are accurately recognised to ensure that society remains 121 
protected from any negative (human health) implications following nanomaterial exposure 122 
(Oberdorster et al., 2005). Other particle and fibre types, although not necessarily within the 123 
nanoscale, have been shown to cause adverse health effects in humans in the past (for example, 124 
asbestos, particulate air pollution and crystalline silica quartz). Thus, questions have been posed 125 
regarding whether exposure to nanomaterials could cause similar or more harmful effects, due to 126 
their small size and potential distribution patterns in the lung and other organs (Donaldson and 127 
Borm, 1998, Donaldson et al., 2010, Stoeger et al., 2006). 128 
An expert Working Group of European regulators, academics and industry scientists led by the UK’s 129 
National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 130 
have identified the potential opportunities being offered in the short, medium and long-term to 131 
reduce the reliance on traditionally used animal toxicology tests whilst advancing the science of 132 
alternative testing strategies towards the risk assessment of nanomaterials. We also explore what is 133 
needed from the nanotoxicology community to ensure these endeavours are translated into genuine 134 
gains in the science and practice of nanomaterial safety assessment, and consider these issues in the 135 
wider legislative context. It is also important to note that the resulting recommendations may also 136 
be widely applicable to other areas of risk assessment that are seeking to move away from the use 137 
of animal toxicity tests (Burden et al., 2015).  138 
 139 
2. The current landscape: in vivo testing strategies within the nanotoxicology field 140 
Within the field, there is an increased desire to replace animal testing with alternative testing 141 
strategies when assessing nanomaterial toxicity. However there are a number of reasons why some 142 
animal toxicity tests will continue to be necessary in the risk assessment of nanomaterials and other 143 
(non-cosmetic) chemicals in the next five to ten years. Firstly, despite extensive research efforts, 144 
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there is still a limited understanding of nanomaterial absorption, distribution, stability and 145 
persistence in the (human) body (Landsiedel et al., 2012), largely due to technological challenges 146 
associated with detection of small quantities of (unlabelled) nanomaterials. Whole organisms 147 
continue to be the most scientifically relevant test system as they are capable of capturing effects of 148 
nanomaterials after they have been absorbed and distributed (and possibly bio-processed) in the 149 
body.  Furthermore, standard testing requirements in many regulations demand data from animal 150 
experiments, and risk assessors are most experienced, and have most confidence, in interpreting 151 
data from animal models. There is also insufficient knowledge of how results generated using non-152 
animal methods compare with data from traditional in vivo tests, due to a lack of published studies 153 
focused on directly comparing effects seen using alternative models (e.g. in vitro, in chemico, 154 
invertebrate models) against those observed in vivo (e.g. (Snyder-Talkington et al., 2015, Landsiedel 155 
et al., 2014b, Krug, 2014)). 156 
The majority of in vivo assessments undertaken so far have been intended to assess the effects of 157 
inhalation exposure to nanomaterials, as currently the primary populations at risk of exposure to 158 
nanomaterials are those working in  industry, and thus occupational exposure via inhalation 159 
represents a high-priority group (Shatkin and Kim, 2015). Therefore to reflect this exposure route of 160 
concern, more pulmonary-orientated research than oral-based studies tends to be performed for 161 
nanomaterials (Stone et al., 2016a, Aschberger et al., 2016). Inhalation studies require specialised 162 
equipment and are more difficult and expensive to carry out than oral administration studies which 163 
are commonly used for other chemicals and products. Hazard assessment of nanomaterials has 164 
therefore largely utilised in vivo studies carried out using high dose intratracheal instillation, with 165 
post-exposure observation periods which are often selected to mimic accumulations resulting from 166 
chronic (low dose) exposure. The high doses tested and route of administration employed in these 167 
studies are not always relevant to human exposure scenarios, and can result in so-called “overload” 168 
of the test system (Morrow, 1988, Oberdorster et al., 2015). To address this, protocols such as short-169 
term in vivo inhalation studies (STIS) have been developed and advanced, in order to increase 170 
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understanding of the effects of inhaled nanomaterials and thus potentially reduce the need for 90-171 
day inhalation studies (OECD Test Guideline 413) (Hahn et al., 2014, Ma-Hock et al., 2009, Landsiedel 172 
et al., 2014a). Adoption of the STIS protocol in research studies such as the EU funded Sustainable 173 
Nanotechnologies (SUN) project (www.sun-fp7.eu/) has reduced the time, financial and ethical 174 
implications associated with testing nanomaterial safety, but have not yet eradicated the need for 175 
longer term tests (Gosens et al., 2016).  176 
Although the long-term effects of nanomaterial exposure remain a major safety concern, there are 177 
few inhalation laboratories equipped to carry out the time consuming and expensive sub-chronic 178 
(i.e. 90 day) or chronic (1.5 to 2 year) OECD inhalation tests, and thus there remains limited available 179 
animal data on the chronic effects of inhaled nanomaterials, e.g. (Ferin et al., 1992, Pothmann et al., 180 
2015, Kasai et al., 2016). Furthermore, there is uncertainty when extrapolating from short-term in 181 
vivo studies to chronic effects due to limited knowledge regarding nanomaterial biokinetics and 182 
accumulation in the human body, and on the progression of short-term effects into adverse, chronic 183 
biological impacts. 184 
Exposure assessments, which aid in the risk assessment process, are carried out with a focus on the 185 
release of nanomaterials over the life cycle of the products and actual aerosol concentrations in the 186 
air, with less focus on the determination of the internal body/circulating concentrations that result 187 
from such exposure (Pelclova et al., 2017). Furthermore, the patterns of exposure are likely to 188 
change over coming years as the industry grows. Although inhalation exposure to nanomaterials 189 
currently remains the primary portal of entry largely as a result of occupational exposure, effects on 190 
consumers following exposure via oral and dermal routes are becoming more relevant due to the 191 
wide array of potential applications possible for nanomaterials (e.g. in cosmetics, food or consumer 192 
products), and the increase in nanomaterials on the market. Few data are available as yet on uptake 193 
and effects through oral and dermal routes (Stone et al., 2016a), as particulate materials including 194 
nanomaterials are typically not often absorbed through intact skin (e.g. see SCCS, 2012). This is a 195 
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major challenge in terms of increasing interest in the use of nanomaterials for the transdermal 196 
delivery of therapeutics (e.g. reviewed in (Peptu et al., 2015), and the use of specifically-designed 197 
nanomaterials for this purpose is a further concern regarding the testing necessary to determine 198 
dermal toxicity of nanomaterials. As many nanomaterials intended for dermal application are most 199 
likely to be found within cosmetic products, and cosmetics are no longer allowed to be tested on 200 
animals in many regions, viable alternatives to models of in vivo dermal exposure will be critical in 201 
coming years. In fact, the OECD has issued guidance on an integrated approach to testing and 202 
assessment (IATA; OECD 2014) which is based on alternative methods that should be employed 203 
when assessing the skin irritation and sensitisation potential of chemicals (OECD, 2014b; OECD 204 
2016a; OECD 2016b), and this IATA should be applied to nanomaterials. 205 
The discussion on how to best assess the safety of NMs throughout their life-cycle may trigger the 206 
use of large numbers of animals and resources. Furthermore, insufficient knowledge on how stable 207 
nanomaterials are during transit within the body and their fate is adding to uncertainty around the 208 
utility of data generated in both in vivo and in vitro studies. Efforts have begun to investigate the 209 
stability/degradation of nanomaterials in relevant “body fluid” environments (e.g. (Kagan et al., 210 
2010, Feliu et al., 2016)) and the influence that the formation of nanomaterial–protein complexes 211 
(which occurs following nanomaterial exposure, or during their transit in the body) has on the 212 
biological response (e.g. (Lundqvist et al., 2011), although there remains a lack of controlled studies 213 
which systemically address these questions. The plethora of nanomaterials/forms requiring 214 
investigation also means it is impractical to perform in vivo studies for every single 215 
nanomaterial/form.  Furthermore, there are general questions being asked in aligned fields such as 216 
traditional chemical risk assessment, regarding whether data generated from animal studies really 217 
are the most appropriate means of predicting human hazards (Hartung, 2009).  218 
There are also increasing business and legislative drivers towards the re-evaluation of the use of 219 
animal toxicity tests; for example risk assessments for the cosmetics/personal care products industry 220 
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in Europe (EU Cosmetics Regulation 1223/2009/EC) cannot be carried out in animals. Similar bans 221 
are also in place or expected in other geographical regions. This could drastically impact innovation 222 
in the development of novel nanomaterial ingredients if suitable alternative methods for gathering 223 
safety data are not sought quickly. Other regulations stipulate that animal tests are only carried out 224 
as a last resort, e.g. the European chemicals legislation REACH (Registration, Evaluation, 225 
Authorisation & restriction of Chemicals), even though animal toxicity tests remain the standard 226 
means to fill the information requirements.  227 
 228 
3. The vision: aligning the 3Rs with improved safety assessment of nanomaterials 229 
Creating an environment where the use of animals in nanotoxicology is refined, reduced and 230 
replaced would help to address societal, business and legislative concerns, and could at the same 231 
time could improve the science underlying the safety assessment of nanomaterials. However, a 232 
systematic and focused shift towards this vision, and a clearly co-ordinated strategy to enable this 233 
will be needed. There is currently an opportunity to create a scientifically-driven paradigm which 234 
takes advantage of all the latest scientific and technological developments (Stone et al., 2016b, 235 
Hussain et al., 2015) and applies them to promote a “21st century” approach to the risk assessment 236 
of nanomaterials. Here we consider the opportunities currently available or under development that 237 
within short, medium and long-term timeframes could allow these goals to be achieved. 238 
 239 
3.1 Immediately, and in the short term (0-5 years): Reduction and refinement of existing 240 
animal models  241 
It is possible to immediately refine (i.e. minimise pain, suffering, distress or lasting harm) and reduce 242 
the numbers of animal tests that are currently carried out to assess the safety of nanomaterials. For 243 
example, the application of short-term inhalation studies (Landsiedel et al., 2014a), where rats are 244 
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exposed to test material aerosols on five consecutive days with 21- or 28-day post-exposure 245 
observations could, in the first instance, serve as an early tier test. This would determine whether 246 
further sub-chronic and chronic toxicity tests need to be carried out, and in this way would decrease 247 
the number of longer term studies. Indeed, as more data from this type of study becomes available 248 
it could be used as a screening and grouping tool and hence reduce the need for 90 day in vivo 249 
studies altogether. It is worth noting that the progression of effects and chronic outcome may not be 250 
detected in such a study e.g. those which result from biopersistence. Therefore it is crucial that 251 
considerations around the fitness for purpose of short-term studies are made on a case by case basis 252 
(as has been previously shown in (Ferin et al., 1992) and (Oberdörster et al., 1990)). There is also 253 
potential to combine several endpoints within each animal study, and determine toxicity at both the 254 
exposure site (e.g. lungs) and secondary target site (e.g. liver) to maximise the amount of 255 
information obtained from each study (e.g. see (Gosens et al., 2015)). Inhalation studies have been 256 
carried out which combine organ toxicity, genotoxicity and (albeit limited) biokinetic examinations 257 
(Landsiedel et al., 2014a, Cordelli et al., 2017, Maser et al., 2015).  Such an approach is frequently 258 
applied to academic in vivo studies, as shown by several previous studies that have assessed a 259 
number of biological responses (e.g. inflammation and oxidative stress) in order to better 260 
understand the potential mechanisms underlying the adverse biological impact associated with 261 
nanomaterials at different target sites (Cockburn et al., 2012, Poland et al., 2008, Shvedova et al., 262 
2005, Labib et al., 2016). Furthermore, European Commission-funded projects frequently perform in 263 
vivo studies that share tissues between laboratories in order to enable assessment of toxicity at 264 
several target sites in one study (e.g. (Kermanizadeh et al., 2016). 265 
Increased incorporation of real-life exposure considerations when designing studies will aid in the 266 
application of tiered approaches which can be used to prioritise or waive testing. This could mean 267 
that nanomaterials are only tested in long-term animal studies if evidence (from in vitro testing) has 268 
been gathered first which shows that there is a genuine potential risk. In this way assessments 269 
would not only explore hazard potential but would also consider whether a) the nanomaterial is 270 
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absorbed, b) long-term exposures are likely, c) sufficient quantities reach the target organ, and d) 271 
systemic effects are caused at the doses tested. When appropriate, such an approach could provide 272 
justification for exposure-based waiving (an option under REACH guidelines). Such a concern-driven 273 
approach based on realistic exposure information is suggested by the EU-funded “Nano-safety 274 
cluster” (Oomen et al., 2014), and considerations of exposure are advised under the Scientific 275 
Committee on Consumer Safety (SCCS) Guidance on the safety assessment of nanomaterial in 276 
cosmetics, and European Food Safety Agency (EFSA) Guidance on the risk assessment of the 277 
applications of nanoscience and nanotechnologies in the food and feed chain. There would be great 278 
benefit in utilising evidence from clinical data on nanomaterial effects more widely, particularly to 279 
aid understanding around likely human exposure levels, and also when evaluating the predictive 280 
nature of both animal and non-animal approaches (see Table 1), although it is unclear how much of 281 
this information exists or is likely to be generated in this timeframe. Additional information could 282 
come from biomonitoring data from occupational settings, as well as initiatives that provide 283 
information on the exposure levels to nanomaterials that are possible following contact with, for 284 
example, different cosmetics and food products. 285 
The addition of toxicokinetic analyses to short term in vivo studies could help with dose setting for 286 
subsequent chronic in vivo studies, as is the case for chemicals (Creton et al., 2012). Such analyses 287 
could be used to determine the relationship between internal exposure and systemic effects. This 288 
information is particularly important considering that internal exposure can be influenced by pre-289 
absorption behaviour of the nanomaterial (e.g. agglomeration/aggregation (Pauluhn, 2010)), or the 290 
dose selected, as administration of excessively high doses may lead to higher or lower 291 
(agglomeration, and thus) exposures (Oberdorster et al., 2015). These effects highlight the 292 
importance of ensuring that the doses selected for testing are relevant to levels likely to be 293 
encountered by humans and the environment, and to enable cross-species extrapolation. To date, 294 
assessment of nanomaterial biodistribution has relied on the use of labelled (e.g. fluorescent, 295 
radioactive) nanomaterials (e.g. (Konduru et al., 2014). Fluorescence labels may produce artefacts in 296 
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biological systems which are not related to the nanomaterial itself (Johnston et al., 2013). Elemental 297 
analysis has also been used to detect and quantify nanomaterial (e.g silver) biodistribution, but this 298 
approach cannot discriminate between particles or ions. Thus new approaches are required to 299 
enable the biodistribution of the diverse array of unlabelled nanomaterials to be performed (for 300 
example, the use of Coherent Anti-Stokes Raman Scattering (CARS) microscopy to image particle 301 
uptake by cells/tissues; (Johnston et al., 2015). 302 
A further area of importance is the current efforts to evaluate, improve and validate current 303 
standard in vitro test systems for nanomaterial hazard assessment. There is an appreciation that 304 
approaches which already have associated OECD Test Guidelines are not always appropriate for 305 
nanomaterial testing, and thus there are ongoing activities to address these issues to recommend  306 
protocols developed specifically for nanomaterial evaluation (Doak et al., 2012, Pfuhler et al., 2013, 307 
OECD, 2014a, Oesch and Landsiedel, 2012, Rasmussen et al., 2016). These efforts will help to redress 308 
the problems associated with the relevance and reliability of current in vitro assays for 309 
nanomaterials, but new test systems may still be required, as it is unlikely that the current models 310 
are able to adequately report on all mechanisms leading to adverse effects potentially induced by 311 
nanomaterials (Doak et al., 2012, Hirsch et al., 2011). Building knowledge about the mode of action 312 
of nanomaterial toxicity (i.e. the cellular and molecular processes driving pathogenicity) will enable 313 
informed, evidence based in vitro models to be identified, which can be used in the first instance to 314 
screen for nanomaterial toxicity and could reduce the number of nanomaterials taken forward for in 315 
vivo testing. There is also scope to apply knowledge of how other non-nano-sized particles and fibres 316 
behave, to identify and inform which responses are of most importance and interest when assessing 317 
nanomaterial hazard. The OECD has recommended a testing strategy for assessment of skin 318 
irritation and sensitisation which uses models of varied complexity, including in vitro and in chemico 319 
test systems (OECD, 2014b), OECD 2016a, OECD 2016b). These protocols have not been widely 320 
applied to nanomaterial risk assessment (e.g. for eye irritation testing see (Kolle et al., 2016), but 321 
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offer an opportunity to enhance the use of alternative models by the nanotoxicology community and 322 
should be more widely used in the future.  323 
 324 
3.2 In the medium term (5-10 years): Reduction of animal use through use of existing 325 
information, development of more robust, targeted in vitro approaches and more 326 
predictive computational models 327 
There is scope to leverage existing information to prioritise nanomaterials for testing. One way to 328 
achieve this is through grouping, to allow the utilisation of read-across approaches and provide 329 
justification for waiving of tests. There is however recognition within the field that the grouping of 330 
nanomaterials is complicated and cannot be reliably carried out based on properties such as 331 
chemical composition, size or surface coating alone, as the links between these and any adverse 332 
biological impacts are complex (Braakhuis et al., 2016). Thus, there has been a need to categorically 333 
identify the most appropriate and relevant factors which causally lead to apical endpoints. Currently 334 
the most straightforward comparison that can be made is to the bulk counterpart of a nanomaterial, 335 
for which there usually exists documented evidence on toxicity and also information on human 336 
exposure (Cockburn et al., 2012). So far, a robust structure activity relationship and a good 337 
correlation between in vitro and in vivo studies have been identified for asbestos fibres and carbon 338 
nanotubes (Poland et al., 2008, Brown et al., 2007) and work is ongoing to establish such 339 
correlations for other types of nanomaterial. Accordingly, existing knowledge on the intrinsic and 340 
system-dependent physicochemical properties of nanomaterials which confer toxicity can support 341 
evidence based, tiered approaches to testing their pathogenicity. For example in the case of high 342 
aspect ratio nanomaterials (HARNs) such as carbon nanotubes (CNTs) fibre length has been 343 
correlated to both in vivo effects (e.g. inflammation), with increasing fibre length (>5µm) causing 344 
greater toxicity (Donaldson et al., 2010). The HARN concept has not yet been adopted for two-345 
dimensional materials, like graphene. This effect has also been observed in vitro when macrophages 346 
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are used as the test system via assessment of the following indicators of toxicity; cytotoxicity, 347 
proinflammatory cytokine production, cellular uptake, and ROS production (Kermanizadeh et al., 348 
2013, Brown et al., 2007). Accordingly, for assessing the safety of these types of nanomaterial, the 349 
first key step would be identifying fibre length and diameter using (electron) microscopy. It would 350 
also be informative to assess the purity of samples through elemental analysis, as iron and nickel 351 
contaminants are known to contribute to CNT toxicity (Lam et al., 2004). This would be followed by 352 
assessment of in vitro macrophage responses (Wiemann et al., 2016) for HARN samples with 353 
physicochemical properties of concern (e.g. fibre length, metal content, diameter), followed by 354 
targeted in vivo testing to confirm in vitro findings, and fulfil data requirements (Stone et al., 2016a). 355 
Quantitative Structure Activity Relationship (QSAR) models that can be used for prediction of 356 
nanomaterial exposure-dose-responseare currently under development for metal-based 357 
nanomaterials (Kleandrova et al., 2014, Winkler et al., 2014). There have also been significant efforts 358 
in the field focusing on QSAR models and physiologically based pharmaco-kinetics (PBPK) models to 359 
predict in vivo nanomaterial exposure hazards for human and aquatic organisms developed in FP7 360 
European projects including SUN, ENPRA, MARINA and MODENA-COST, designed to provide a basis 361 
for in vitro / in vivo extrapolations (IVIVE)(Speck-Planche et al., 2015, Puzyn et al., 2011, Winkler et 362 
al., 2013, Lin et al., 2016, Carlander et al., 2016, Li et al., 2016). However, whilst such computational 363 
models can complement experimental work (Horev-Azaria et al., 2011) they cannot, at this time, 364 
replace it and there has been limited success in facilitating IVIVE (Lin et al., 2016). For example, as 365 
the extrinsic properties of nanomaterials dynamically change according to the biological 366 
environment, correlation of in vivo/in vitro test results with their pristine structure and/or intrinsic 367 
properties (i.e. the classic (Q)SAR approach) is insufficient. Quantitative Structure-Property 368 
Relationships (QSPR) therefore need to be established and also represent an area of increasing focus 369 
requiring further development as our understanding of nanomaterial behaviour in complex 370 
biological environments improves (Winkler et al., 2013, Hristozov et al., 2014). Thus, at this time 371 
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much work will be required to make these models suitable for regulatory risk assessment (Tantra et 372 
al., 2015, Winkler et al., 2013).  373 
The enormous diversity of nanomaterials and models (e.g. mammalian cells, rodents, humans, 374 
aquatic organisms, terrestrial organisms, plants, bacteria) that must be considered is a barrier to the 375 
fast development of QSARs (Kleandrova et al., 2014). As such, high throughput (HTP) automated 376 
systems which can be used to fill data gaps are desirable to enable the generation of sufficiently 377 
predictive QSAR models. Relating material properties to biological outcomes will also be useful in 378 
read-across approaches, and the large body of data recently released from the OECD 379 
(www.oecd.org/chemicalsafety/nanosafety/testing-programme-manufactured-nanomaterials.htm) 380 
had potential to contribute relevant information on major nanomaterials that could form part of the 381 
reference base for improved read-across (Foss Hansen et al., 2016). Recently a decision making 382 
framework for the grouping and testing of nanomaterials for human health assessments has been 383 
proposed by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) “Nano 384 
Task Force” (DF4nanoGrouping; (Arts et al., 2015, Arts et al., 2016)) which aims to ensure that in vivo 385 
studies are only performed where there are specific data needs, i.e. when read-across cannot be 386 
performed, or when the data supporting read-across is not sufficient. The grouping process 387 
proposed considers information such as exposure, the characteristics responsible for the 388 
functionality of the nanomaterials (e.g. uptake and system-dependent properties including solubility, 389 
agglomeration, dispersibility), and cellular effects (i.e. mechanisms of action), and the link between 390 
these factors and apical endpoints. Work is ongoing to build confidence in this strategy (RIVM, JRC, 391 
and ECHA, 2016; OECD 2016c); other factors that will benefit from further investigation within a 392 
grouping approach include: a) the physicochemical characteristics known to drive biological 393 
interactions (including shape and surface area of the nanomaterial); b) the ability of the 394 
nanomaterial to enter different cellular compartments (thus allowing for the possibility of a variety 395 
of biological responses); and c) the number of nanoparticles interacting with cells. The intention is 396 
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that a robust grouping approach could be incorporated into regulatory guidance in the medium 397 
term, to enable its application at the broader level. 398 
Expanding the use of in vitro approaches that are specifically targeted towards the fulfilment of data 399 
requirements could be possible within this time frame. These would include HTP systems to provide 400 
information on nanomaterial physicochemical characteristics, hazards and exposure for use in risk 401 
assessment (as envisioned by the ITS-NANO framework (Stone et al., 2014)). This requires a shift 402 
towards the use of robust, systematic and comprehensive in vitro test platforms that provide an 403 
indication of uptake and biological effects of nanomaterials specifically over a range of toxicity 404 
endpoints, and consideration of how multiple tests can be integrated to allow for accurate 405 
predictions of each endpoint (Clift et al., 2011, Stone et al., 2009, DeLoid et al., 2017). In the 406 
medium-term such information will be gained through the application of currently used in vitro cell-407 
based test systems (e.g., those applied in chemical toxicity tests and used in the nanotoxicology field 408 
currently, as reviewed in (Hartung and Sabbioni, 2011)) or adaptations thereof. In combination with 409 
data from high throughput screening this approach will help to build confidence in the use of cell-410 
based systems and will contribute to gaining useable knowledge about the biological reactivity of 411 
nanomaterials, as well as a better understanding of their toxicological mechanisms. These platforms 412 
may also be used as tools in the early screening of candidate nanomaterials to help ensure that 413 
potential to induce toxicity is detected and further understood prior to a substance being 414 
administered in animal tests (Clift et al., 2014). The animal tests may then be avoided completely if 415 
problematic substances are flagged by these screens, or any necessary animal tests could then be 416 
better designed and refined.  In addition, innovative technologies which utilise microfluidics, such as 417 
“lung-on-a-chip” micro-devices that can accurately replicate specific conditions within the human 418 
lung (Huh et al., 2012), and those which could mimic passage of nanomaterials from the gut through 419 
blood vessels to the liver (such as (Kim et al., 2016) or that developed in the inlivetox project: 420 
http://www.inlivetox.eu/), are becoming available and have potential to contribute useful 421 
physiologically relevant information.  Concomitant to such progression within cell based in vitro 422 
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technologies, it should be noted that similar achievements are also being made within 423 
computational toxicology, as recently reviewed in (Richarz et al., 2015). As efforts continue in the 424 
development of nano-specific in vitro tests, it is conceivable that in the medium-term useful models 425 
that are currently available may have progressed towards validation.  426 
While efforts in each of these areas are ongoing, it is important that investment continues into 427 
refining and reducing the numbers of animals used in the in vivo tests that remain mandatory, and 428 
from which information will be used to inform the utility of the new/adapted in vitro approaches. 429 
For example, developing short-term studies for routes other than inhalation (e.g., short term studies 430 
for oral administration are being developed as part of the EU-funded project SUN), and improving 431 
the technical aspects of STIS, particularly as aerosol generation and characterisation is demanding. 432 
Moreover, it is challenging to model actual lung burdens resulting from aerosol inhalation in vitro. 433 
However, strides have been taken to close this gap, for example in a recent publication where the 434 
occupational exposure of an inhalatory dose of carbon nanotubes could be mimicked based upon 435 
their physicochemical characteristics (Chortarea et al., 2015). 436 
 437 
3.3 In the long term (10 years +): Replacement with accepted non-animal methods 438 
In the long-term many sectors have a desire to move away completely from using animal toxicity 439 
tests towards the use of scientifically and regulatory accepted non-animal approaches which bear 440 
greater relevance to humans. Like traditional in vivo tests, each non-animal method has its own 441 
merits and disadvantages, and it is unlikely that one cell-based assay or computational model will 442 
ever replace an existing animal test on a 1:1 basis. Thus, the most appropriate methodologies will 443 
need to be applied in an integrated assessment and testing strategy (Landsiedel, 2015), which 444 
includes weight of evidence considerations. This will negate the use of a predefined test battery 445 
even with suitable in vitro methods at hand.  This will also mean that data packages may need to be 446 
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designed on a case-by-case basis i.e. in a pragmatic, tiered manner which addresses the necessary 447 
data gaps, rather than a conventional “tick-box” approach. 448 
Exposure considerations will form an important component of such an integrated approach and 449 
could start to be addressed in vitro through the incorporation of barrier models, which have 450 
potential to allow for investigations into nanomaterial uptake and transport (Bachler et al., 2015, 451 
Braakhuis et al., 2015, Endes et al., 2015, Garcia-Garcia et al., 2005, George et al., 2015, Rothen-452 
Rutishauser et al., 2007, Gordon et al., 2015). More complex in vitro models will also be important in 453 
providing information on barrier penetration and translocation capabilities, such as those which 454 
comprise more realistic and physiologically relevant systems than the traditional 2D/monolayer 455 
methods. This includes cultures of multiple cell types and growing cells in 3D, which has been 456 
demonstrated in the “ready to use” EpiDermTM system, which more accurately mimics skin (although 457 
these types of commercial platforms tend to be expensive) (Wills et al., 2016). Also, the use of 458 
human or pig skin explants are used to estimate dermal uptake of nanomaterials (Monteiro-Riviere 459 
et al., 2013, Fabian et al., 2016). Three-dimensional tissue models demonstrate functional and 460 
metabolic properties that could be considered more representative of the in vivo environment, as 461 
recently suggested for the identification of eye irritation potential of nanomaterials (Kolle et al., 462 
2016) . Consequently, biological response and outcomes seen in 3D and microfluidics models in 463 
relation to toxicity endpoints may be very different to those observed in 2D culture systems, which 464 
suggests that they may be more physiologically representative (Chapman et al., 2014, Hu et al., 465 
2010, Clift et al., 2014, Snyder-Talkington et al., 2015, Ucciferri et al., 2014). An emphasis on using 466 
human cells and tissues in such models where possible will further increase their relevance in the 467 
assessment of human safety. 468 
Determining whether the endpoints or biomarkers measured within in vitro tests are truly driving 469 
the key events that result in adverse effects at an organism level would be facilitated by an increased 470 
understanding of mechanisms/modes of action; sufficient acquisition of this type of knowledge 471 
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could facilitate in the long-term the subsequent development of adverse outcome pathways (AOPs) 472 
specific for nanomaterials. Mapping out the pathways in the systematic manner offered by the AOP 473 
paradigm would also help to identify research and data gaps in the toxicity pathways triggered by 474 
harmful nanomaterials. This has started to be explored e.g. see (Wang et al., 2015), and under the 475 
auspices of the EU’s MARINA, NanoSafetyCluster and ITS-NANO (Stone et al., 2014) projects. 476 
Application of pathways-based approaches has the potential to improve mechanistic understanding 477 
of nanomaterial effects (Nel et al., 2013), and advance the development and implementation of non-478 
animal methods to determine whether substances are likely to cause the key events that result in 479 
adverse outcomes. Again, it is crucial that an exposure element is captured in such an activity, a 480 
feature not encompassed by the current AOP paradigm. Reliable and advanced in silico models, if 481 
progressed through the availability of more hazard and physicochemical data generated for example 482 
by high throughput systems, could also offer huge benefits to the field in the long-term, and will be 483 
key tools for predicting the likelihood of different nanomaterials to induce the key events within 484 
toxicity pathways. Large-scale efforts towards such modelling approaches have already been 485 
initiated, with projects such as the COST Action TD1204 Modelling Nanomaterial Toxicity (MODENA): 486 
http://www.cost.eu/COST_Actions/mpns/Actions/TD1204. 487 
 488 
4. Key objectives to achieve the vision 489 
The ultimate aspiration of aligning the 3Rs principles with nanotoxicology is the efficient and reliable 490 
risk assessment of nanomaterials through application of a focused, exposure-driven integrated 491 
approach which utilises data from animal studies only where it genuinely adds value and 492 
concentrates testing on specific scientific questions, feeding back into safe-by-design nanomaterials. 493 
Table 1 outlines the expert group’s perspective on the key focus areas resulting from the short, 494 
medium and long-term goals and the necessary steps to enable this vision, while Figure 1 495 
summarises the major scientific considerations needed in approaching these objectives. It is worth 496 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
noting that within the coming years, more information on exposure and effects of nanomaterials will 497 
come to light, and this experience should be considered and these steps revised accordingly 498 
(Nowack et al., 2016, Sotiriou et al., 2016, Ding et al., 2017). 499 
 500 
5. Outlook 501 
This broad level analysis focuses on how the application of non-animal methods could drive 502 
advances in the field of nanotoxicology and the potential next steps to achieve this. The proposals 503 
have widespread applicability and are relevant across multiple sectors. By prioritising attention on 504 
the key focus areas identified in section 4 we recommend that the toxicology community work 505 
together to: 506 
 Evaluate and acknowledge the limitations and uncertainties of all in vivo and in vitro approaches, 507 
both traditional and alternative; 508 
 Provide clarity as to which potential effects can be adequately covered in safety assessment and 509 
which potential effects require further research;  510 
 Appreciate that there will never be a single system that is suitable for  all nanomaterials - 511 
different models/frameworks/integrated approaches (some of which are already available) 512 
covering different aspects of several nanomaterials, will prove helpful; ultimately a battery of 513 
approaches will cover most nanomaterials;  514 
 Design exposure-driven integrated approaches/decision-making frameworks first then seek the 515 
methods that provide the appropriate data for this specific purpose. 516 
 517 
Achieving the above will rely on: 518 
 Academic scientists to work on systematically addressing the data gaps identified here, and 519 
strategically focus and align research; 520 
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 Funding bodies, to establish strategic funding calls which have measureable impact and 521 
enable the necessary progress within basic research; 522 
 Regulators, to provide guidance on when they can accept non-traditional approaches and 523 
data (via case studies, to increase the efficiency of the case-by-case approach that is 524 
recommended); and to offer compromise between relying on new approaches and 525 
established methods of risk assessment, and adopting non-animal approaches. During the 526 
time in which data from both in vivo and non-animal tests is being produced, their 527 
concurrent consideration will help to maximise understanding of the merits and 528 
disadvantages of both approaches; 529 
 Industry, to provide clarity about their needs and requirements, to support the steering of 530 
future research efforts. 531 
Finally, the output of these discussions will most likely translate into tangible impacts on the 532 
reduction, refinement and replacement of animals with 1) the engagement and support from 533 
scientific organisations such as the NC3Rs that is complementary to the efforts of the OECD’s 534 
Working Party on Nanotechnology, and 2) open, face-to-face discussion and collaboration which 535 
incorporates dialogue between all relevant stakeholders (regulators, legislators, funders, industry 536 
and academics). 537 
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Table 1. Key focus areas resulting from the short, medium and long-term goals and the steps 904 
necessary to enable them.  905 
 906 
Key focus areas Steps to enable focus areas 
Regulatory framework 
 
Framework established to enable 
implementation of alternative 
non-animal methods into risk 
assessment and acceptance, with 
built-in recognition that it is likely 
that no single method for hazard 
assessment or physicochemical 
data will suffice in isolation 
 Developing methods to serve specific data 
requirements of decision-making frameworks. 
 Validation/standardisation of (alternative) test 
methods towards their use in hazard and risk 
assessment. 
 Increasing regulatory confidence in results from non-
traditional methods (via guidelines, training, 
workshops, dialogue). 
 Supporting risk assessors to understand the relevance 
and applicability of in vitro data for risk assessment, 
particularly as there will be a need for extensive 
resource and expertise to interpret and integrate data 
from various sources.  
 Adoption of a rationale to deal with uncertainties and 
limitations inherent to experimental models (both in 
vitro and in vivo). 
 Ensuring that uncertainty in the results is reflected 
clearly by risk assessors. 
 Applying a weight of evidence approach to consider 
all available evidence from different non-animal 
methods. 
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 Engagement of decision makers early on in the 
process. 
Hazard prediction 
 
Accurate predictions of toxicity 
that can be confidently linked to 
physicochemical properties (not 
only material properties of the 
pristine material but also 
functionality of the nanomaterial, 
e.g. bio-physical interactions of 
the nanomaterial with its 
environment (e.g. body fluids))  
 
 Adoption of a dual approach: hypothesis driven 
studies which test if a particular nanomaterial 
property impacts on toxicity, and studies which 
compare the toxicity of panels of nanomaterials. 
These parallel approaches will aim to identify which 
properties confer toxicity. 
 Production and easier access to series of 
systematically altered nanomaterials (e.g. different 
nanomaterials of the same material with one 
characteristic altered to enable hypothesis-driven 
studies to be performed; although we recognise this 
could prove challenging). 
 Standardisation of measurements and methods used 
for nanomaterial characterisation.  
 Continuation of data sharing on the characterisation 
of nanomaterials and hazard information in order to 
document properties and make connections to 
adverse outcomes, as is taking place within certain EU 
projects (via round-robin exercises, etc.). 
 Pooling existing toxicity and physicochemical data 
and analysing trends to enable predictions, providing 
the data is comparable and reliable (i.e. all variables 
are kept the same). 
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 Establishment of “reference data” for different 
endpoints for nanomaterials or other well-known 
particulate materials (e.g. silica or asbestos) which are 
deemed “representative” (dependent on the 
nanomaterial being studied) and the use of 
appropriate positive controls to relate the effects of 
the nanoforms in vitro/in vivo. This involves ensuring 
that knowledge already in existence in other areas of 
particle toxicology is utilised to help build knowledge 
within the discipline of nanotoxicology. 
 Development of advanced analytical techniques to 
ascertain levels of exposure. 
IVIVE (in vitro to in vivo 
extrapolation) 
 
Increased understanding of 
extrapolation between different 
in vivo and in vitro models (both 
in vivo vs. in vitro and between 
different in vitro models) 
 
 Selection of relevant concentrations in in vitro 
models. 
 Identification of appropriate positive 
controls/“benchmark” nanomaterials, and 
comparable studies undertaken using them; this 
would be useful in potency ranking for hazard 
identification.  
 Incorporation of toxicokinetic aspects into tests to 
enable consistent assurance that nanomaterials are 
being taken up, and reaching targets and leading to 
systemic exposure.  
 Cross-talk between in vivo and in vitro scientists and a 
culture shift away from treating each in isolation; this 
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has been an aim of projects such as ENPRA in the EU. 
 Focused efforts to bridge the in vivo/in vitro divide 
through targeted investment into developing and 
better understanding the utility of 3D models, fluidic 
dynamic models and multi-cellular cultures. 
 Development of in vitro models that allow repeat-
dosing to be performed. 
 Taking into account the utility of other emerging 
technologies that can provide at least a part of the 
evidence, such as ‘omics’.  
 Enhanced investigation of mode of action of 
nanomaterial toxicity. 
Validation 
 
Consensus reached on how best 
to validate non-animal 
approaches: against a) animal or 
b) human data, considering that 
human is the species in question, 
and many in vitro approaches 
utilise cells of human origin 
 For a), generation of sufficient in vivo data, to enable 
comparisons. This should only be carried out when 
necessary, in situations where the data are critical 
and meaningful (i.e. ensuring that exposure and test 
nanomaterial are well characterised, although 
considering the multitude of possible nanomaterials 
and exposure routes, this will be difficult to achieve, 
but may be aided by grouping approaches). 
 For b), exploitation of clinical/biomonitoring 
information (i.e. from the welding/mining/tattooing 
industries), gathering information from workplaces 
and environments where nanomaterials are used, 
and building knowledge of precisely the 
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concentrations and constituents of nanomaterials 
within widely used products such as cosmetics and 
food additives. 
Mode of action/AOPs 
 
Adaptation of current standard in 
vitro approaches and improved 
test item preparation, dosing, and 
understanding of toxicity 
mechanisms; followed by 
utilisation of the mechanistic data 
they provide to build AOPs 
 Concerted efforts to target areas where current in 
vitro methods are not adequate (e.g. alveolar 
absorption), where the entire range of toxicological 
responses that would be seen in vivo are not 
captured (e.g. lung toxicity), and on better mimicking 
the realistic exposure situation including 
consideration around relevant delivery techniques.  
 Dedicated programmes of work and entering of 
relevant AOPs into the AOP Wiki. 
Publication standards 
 
Raised publication standard so 
that only high quality, relevant 
and comparable information is 
generated in in vitro studies 
 Widespread implementation of standardised 
protocols e.g. which ensure consistency in cell lines 
used, facilitated by ring trials. 
 Studies designed with consideration of the scientific 
question e.g. relevant delivery methods used and 
toxicologically relevant endpoints assessed, 
accounting for system dependent material properties, 
and consideration of in vitro effects on a whole 
organism level e.g. incorporation of components 
which reflect distal effects caused following local 
absorption. 
 Definition and dissemination of scopes and 
limitations of the tests including open recognition by 
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scientists of situations in which in vitro tests may not 
be appropriate e.g. due to  temporal and toxicokinetic 
aspects, and determination of how the predictive 
capabilities of in vitro systems could be utilised in 
these situations.  
QSARs/in silico models 
 
Necessary characteristics and 
essential levels of complexity 
incorporated into computational 
models  
 Extensive collaborations between toxicologists, 
mathematicians and theoretical physicists will 
produce useable, reliable models. 
 Expansion of the use of high throughput systems 
which will enable data gaps to be filled more quickly. 
 907 
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Figure legends 909 
Figure 1. Key scientific considerations to enable realisation of the short, medium and long-term 910 
opportunities outlined in section 3. The boxes on the left hand side detail the tools that are 911 
necessary towards a) ensuring that intrinsic properties and nanomaterial life cycle are considered in 912 
the prioritisation of nanomaterials taken forward into hazard testing, and b) the successful 913 
utilisation of non-animal, mechanistic approaches to predict apical toxic effects. Figure adapted from 914 
that presented at the second International Congress on Safety of Engineered Nanoparticles and 915 
Nanotechnologies (SENN) 2015, Helsinki, Finland by R. Landsiedel. 916 
 917 
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HIGHLIGHTS 
 An expert working group provides a current and forward looking perspective on 
the 3Rs in nanotoxicology 
 Application of non-traditional, alternative methods could improve nanosafety 
assessment 
 There are many short, medium and long-term opportunities to apply the 3Rs 
within nanotoxicology 
 Key focus areas and steps needed to ensure genuine gains are identified. 
